Ustekinumab and vedolizumab are emerging as safe and effective therapies for treating IBD; previously, anti-TNF agents also proved to be efficacious in decreasing surgery and hospitalization rates in both UC and CD patients [22]. The gene discussed is TNF; the disease is inflammatory bowel disease.